問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Rheumatology

Division of General Internal Medicine

更新時間：2023-09-19

羅淑芬Lo, Shue-Fen
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • lsf00076@cgmh.org.tw

Recruiting Trial

37Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

羅淑芬

List

100Cases

2018-03-31 - 2023-12-30

Phase II

A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

  • Condition/Disease

    Moderate to Severe Active Systemic Lupus Erythematosus

  • Test Drug

    GDC-0853

Participate Sites
8Sites

Terminated6Sites

2017-01-01 - 2019-11-30

Phase II

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

  • Condition/Disease

    1. Systemic Lupus Erythematosus and Active Skin Manifestations2. Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

  • Test Drug

    BIIB059

Participate Sites
4Sites

Recruiting4Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2013-04-01 - 2022-12-05

Phase IV

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, AutoantibodyPositive Systemic Lupus Erythematosus Receiving Belimumab

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BENLYSTA (Belimumab)

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

黃春明
China Medical University Hospital

2008-08-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-05-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-07-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2013-05-20 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-10-05 - 2015-10-05

Phase II

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis

  • Condition/Disease

    Active Proliferative Lupus Nephritis

  • Test Drug

    Anifrolumab

Participate Sites
6Sites

Terminated6Sites

2018-04-25 - 2023-07-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Ustekinumab (STELARA)

Participate Sites
10Sites

Terminated8Sites

張棋楨
Taipei Medical University Hospital

羅淑芬
Linkou Chang Gung Medical Foundation

2021-09-10 - 2026-10-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

1 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB